

4.0.03 DOC Cmte minutes

- **Principle** – record the Committee meeting attendance, running, discussions
- **Links to include** – none
- **Attachments to include** – none
- **Info to include** – guideline title; meeting date/location; status of minutes (draft/confirmed); attendees; observers; apologies; agenda items and related discussions; declarations of interest; date of next meeting



Cannabis-based products for medicinal use Committee meeting

Date: 25/04/2019 & 26/04/2019

Location: NICE offices Manchester

Minutes: Draft

Committee members present:	
Steve Pilling (SP) (Chair)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Janine Barnes (JB)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Brigitta Brandner (BB)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Luke Brooker (LBr)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Margred Capel (MC)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Danielle Davis (DD)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Lisa Dolley (LD)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Rachel Farrell (RF)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Vivienne Harpwood (VH)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 2
Renee McCulloch (RM)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 5

4.0.03 DOC Cmte minutes

Andrew McPartlin (AM)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 2
Dermot Murphy (DM)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Claire McVey (CMV)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Finbar O'Callaghan (FOC)	Day 2 – present for notes 1 – 6
David Spraggett (DS)	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6

In attendance:		
Omnia Abdulrazeg (OA)	Senior Technical Analyst	Day 1 – present for notes 1 – 5 Day 2 – present for notes 1 – 6
Louise Bate (LB)	Associate Director Medicines Education/Consultant Clinical Advisor	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Stacey Chang-Douglass (SC)	Technical Analyst - Health Economics	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Clare Dadswell (CD)	Technical Analyst	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Rupert Franklin (RFr)	Senior Guidelines Commissioning Manager	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Leslie Hayes (LH)	Resource Impact Lead	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Ben Johnson (BJ)	Technical Analyst - Health Economics	Day 1 – present for notes 1 – 6
Ross Maconachie (RMC)	Technical Adviser - Health Economics	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6

4.0.03 DOC Cmte minutes

Toby Mercer (TM)	Technical Analyst	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Caroline Mulvihill (CM)	Technical Adviser	Day 1 – present for notes 3 – 6 Day 2 – present for notes 1 – 6
Vonda Murray (VM)	Project Manager	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Joanna Perkins (JP)	Ditigal Editor	Day 1 – present for notes 1 – 2
Shreya Shukla (SS)	Technical Analyst	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6
Sue Spiers (SSp)	Associate Director Guideline Updates Team	Day 1 – present for notes 3 – 6 Day 2 – present for notes 3 – 6
Tom Freeman (TF) – Expert witness	Senior Lecturer Department of Psychology, University of Bath	Day 2 – present for notes 4

Observers:

Dalia Dawoud	Day 2 – present for notes 1 – 3
Anthony Gildea	Day 1 – present for notes 1 – 3
Louisa Regan	Day 1 – present for notes 1 – 6 Day 2 – present for notes 1 – 6

Apologies:

Ben Johnson	Technical Analyst, Health Economics - day 2
Soraya Mayet	Committee member
Finbar O'Callaghan	Committee member
Shelly Patel	Medicines Adviser
Joanna Perkins	Digital Editor – day 1

4.0.03 DOC Cmte minutes

Day 1 - 25/04/2019

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to day 1 of the 4th meeting on Cannabis-based products for medicinal use.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Review of the evidence, and draft recommendations for cannabis-based products for medicinal use and chronic pain.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was cannabis-based products for medicinal use and chronic pain.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Rachel Farrell	Consultant Neurologist	25.04.19	Direct financial	Lecture on MS, and walking impairment, for Merck, in April 2019. An honorarium was paid

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting. The Chair asked the Committee if they were happy with changes to GComm2 minutes, Committee agreed that the minutes were a true and accurate reflection of the meeting.

2. NICE Pathway

4.0.03 DOC Cmte minutes

<p>The Chair introduced JP, Senior digital editor, who gave a presentation on the NICE pathway. The Chair thanked JP for their presentation.</p>
<p>3. Cannabis-based products for medicinal use and chronic pain - clinical evidence</p>
<p>The Chair introduced TM, Technical Analyst, who gave a presentation on the clinical evidence for the use of cannabis-based medicinal products for people with chronic pain. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked TM for their presentation.</p>
<p>4. Cannabis-based products for medicinal use and chronic pain – health economic evidence</p>
<p>The Chair introduced BJ, Technical Analyst – Health Economics, who gave a presentation on the health economic evidence for the use of cannabis-based medicinal products for people with chronic pain. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked BJ for their presentation.</p>
<p>5. Cannabis-based products for medicinal use and chronic pain – draft recommendations</p>
<p>The Committee discussed cannabis-based products for medicinal use and chronic pain.</p>
<p>6. Next steps and AOB</p>
<p>No other business. The Chair thanked the committee for their time and contribution to the meeting. and reminded the committee of the earlier start time for day 2 of the meeting.</p>

Day 2 - 26/04/2019

<p>1. Welcome and objectives for the meeting</p>
<p>The Chair welcomed the Committee members and attendees to day 2 of the 4th meeting on Cannabis-based products for medicinal use.</p> <p>The Chair informed the Committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the objectives of the meeting, which included:</p>

4.0.03 DOC Cmte minutes

- Review of the evidence, and draft recommendations for cannabis-based products for medicinal use and epilepsy.
- Review of the evidence, and draft recommendations relating to the prescribing and monitoring of cannabis-based medicinal products
- Cannabinoid Psychopharmacology

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was cannabis-based products for medicinal use and epilepsy.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, no new interests were declared. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

2. Cannabis-based products for medicinal use and epilepsy – clinical evidence

The Chair introduced CD, Technical Analyst, who gave a presentation on the clinical evidence for the use of cannabis-based medicinal products for people with severe treatment resistant epilepsy. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked CD for their presentation

3. Cannabis-based products for medicinal use prescribing and monitoring - clinical evidence

The Chair introduced SS, Technical Analyst, who gave a presentation on the clinical evidence for the cannabis-based medicinal products prescribing and monitoring. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked SS for their presentation.

4. Cannabinoid Psychopharmacology – expert witness

The Chair introduced TF, Senior Lecturer Department of Psychology, University of Bath who gave a presentation on Cannabinoid Psychopharmacology. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked BJ for their presentation. TF took questions from the group. The Committee thanked TF for their presentation.

5. Cannabis-based products for medicinal use prescribing and monitoring – draft recommendations

The Committee discussed cannabis-based products for medicinal use and chronic pain.

6. Next steps and AOB

4.0.03 DOC Cmte minutes

No other business. The Chair thanked the committee for their time and contribution to the meeting.

Date of next meeting: 28/05/2019 and 29/05/19

Location of next meeting: London